Cardiovascular Diseases

 

Prime Therapeutics research a thumbs up for Entresto — with caveats

November 18, 2020

Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.